University of Calgary
Calgary, Alberta, T2N 4Z6, Canada
Location status: Recruiting
Location contact
Robert S Sheldon, MD, PhD
CONTACT
Satish R Raj, MD, MSCI
CONTACT
NCT Number: NCT05914649
Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).
Interested in participating?
Request Info18 year–60 year
All sexes
Interventional
Not applicable
Calgary, Alberta, T2N 4Z6, Canada
Location status: Recruiting
Robert S Sheldon, MD, PhD
CONTACT
Satish R Raj, MD, MSCI
CONTACT
Many POTS patients report cognitive dysfunction, otherwise referred to as brain fog, mental fog, mental clouding, or mental fatigue. Importantly, this cognitive dysfunction can occur even while lying down or seated, limiting the ability to engage in work and educational activities. Despite the prevalence and clinical impact of cognitive dysfunction in POTS, there are limited studies examining this phenomenon. Many patients with post-acute sequelae of SARS-COV-2 (PASC, or "Long COVID") experience symptoms such as subjective cognitive impairment ("brain fog"), fatigue, memory loss, headache, and fluctuation of blood pressure, amongst other signs and symptoms. Compared to healthy controls, this study will measure cognitive function in patients with POTS and Long COVID. This study will also evaluate IV normal saline (999 mL infusion) as a potential treatment for reduced cognitive function in POTS and Long COVID. This cross-over study will use a 50 mL saline infusion as a placebo control.
The findings from this study will be an initial first step towards understanding any neurocognitive impairment in participants with long COVID and POTS patients. This is a critical first step to future studies to assess underlying pathophysiology and potential treatments.
Primary hypothesis: Some objective measures of neurocognitive functions will improve in Long COVID and POTS patients after the infusion of 999 mL of normal saline compared to 50mL placebo control.
The primary analysis will compare the standing 5RTI task on the CANTAB testing scores between 999 mL saline infusion and 50 mL saline infusion (placebo).
Study Day and Instrumentation:
CANTAB Testing Protocol: CANTAB tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control. The subtests that will be used in this study for seated cognitive function are: Reaction Time Test (psychomotor Speed), Rapid Visual Information processing (Attention), Paired Associates Learning (Visual Episodic Memory), Spatial Span (Working memory), Verbal Recognition Memory (Verbal memory), Multitasking Test (Executive Function - Inhibition), Stocking of Cambridge (Executive Function - Planning) and the Emotional Bias Task (Emotion Processing). All tests are administered using a touchscreen tablet, and participants will respond to each test on-screen. Standardized written and audio instructions are given to participants through the software, and practice trials are completed before each test, reducing practice effects. Seated testing will be completed in approximately 60 minutes. The Reaction Time Test, Rapid Visual Processing and Multi Tasking tests will be repeated upon standing and will take approximately 30 minutes to complete.
After the in-lab portion of the study, participants will complete a series of validated questionnaires through a paper or RedCap secure web application for assessment of psychiatric symptoms. A unique URL link will be sent to the participants via Redcap Survey. These online surveys will take approximately 60 minutes to complete.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
999 mL of IV normal saline will be infused intravenously
50 mL of IV normal saline will be infused intravenously as a placebo control.
Time frame: During Procedure (3 hours)
5RTI Reaction Time Score (Standing) after 999 mL IV saline compared to 5RTI score after 50 mL IV saline measured in milliseconds (ms). The minimum score is 100 ms and the maximum score is 5100 ms. A longer time is a worse outcome.
Time frame: During Procedure (3 hours)
Reaction Time Test score after 1500mL IV saline compared to after 50mL IV saline measured in milliseconds. The minimum score is 100 ms and the maximum score is 5100 ms. A longer time is a worse outcome.
Time frame: During Procedure (3 hours)
Paired Associates Learning score after 999 mL IV saline compared to after 50 mL IV saline measured in arbitrary units. The minimum score is 0 and the maximum score is 70. A higher score is a worse outcome.
Time frame: During Procedure (3 hours)
Verbal Recognition Memory test score after 999 mL IV saline compared to after 50 mL IV saline. The range is 0-18. A higher score is a better outcome.
Time frame: During Procedure (3 hours)
Multitasking Test Time after 999 mL IV saline compared to after 50 mL IV saline measured in ms. The range is 100 - 2000 ms. A longer time is a worse is a worse outcome.
Time frame: During Procedure (10 minutes)
Sitting heart rate after 999 mL IV saline compared to after 50 mL IV saline.
Time frame: During Procedure (10 minutes)
Standing heart rate after 999 mL IV saline compared to after 50 mL IV saline.
Contact information is provided by the study sponsor or research team.
Rasha Hamzeh, RN
CONTACT
Satish R Raj, MD MSCI
CONTACT
University of Calgary
Other
Neurocognitive Testing in Long COVID and Postural Tachycardia Syndrome Patients With Normal Saline: A Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05741112
Autonomic Nervous System Diseases, COVID-19
La Jolla, California, United States
View Trial DetailsNCT05877534
Autonomic Nervous System Diseases, COVID-19
Stockholm, Sweden
View Trial DetailsNCT05633407
Autonomic Nervous System Diseases, COVID-19
La Jolla, California, United States
View Trial DetailsNCT05094622
Autonomic Nervous System Diseases, Behavior
Stockholm, Sweden
View Trial Details